8-K: LENZ Therapeutics Completes Merger with Graphite Bio, Eyes Presbyopia Market with Late-Stage Assets

LENZ Therapeutics has finalized its merger with Graphite Bio, debuting on Nasdaq under the ticker symbol LENZ, and is advancing its late-stage clinical assets for the treatment of presbyopia.

Summary

• LENZ Therapeutics has completed its merger with Graphite Bio, and will now trade on Nasdaq under the symbol LENZ.
• The company is focused on developing eye drops for presbyopia, a condition affecting 128 million people in the U.S.
• LENZ's lead product candidates, LNZ100 and LNZ101, are once-daily eye drops containing aceclidine, with LNZ101 also containing brimonidine.
• Phase 3 CLARITY trial topline results are expected in April 2024, with a potential NDA submission to the FDA by mid-2024.
• The company has approximately $210 million in cash and cash equivalents, including $53.5 million from a concurrent PIPE financing.
• The merger resulted in pre-merger LENZ stockholders owning approximately 56.2% of the combined company, pre-merger Graphite Bio stockholders owning approximately 30.8%, and PIPE investors owning approximately 13.0% on a fully diluted basis.
• The company plans to launch either LNZ100 or LNZ101 in the U.S. with its own commercial organization, and is exploring partnerships for other markets.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting the completion of the merger, the strong cash position, and the upcoming milestones. The company is well-positioned to potentially become a leader in the presbyopia market.

Positives

• The company has a strong cash position of approximately $210 million, which is expected to fund operations through commercialization.
• The company has completed its Phase 3 CLARITY trials and expects to report topline results in April 2024.
• The company has a clear path to NDA submission by mid-2024, subject to successful trial results.
• The company has a strong management team with experience in the ophthalmic and consumer product industries.
• The company has a robust intellectual property portfolio with patent protection until 2039.

Negatives

• The company is still in the clinical stage and has not yet received FDA approval for its product candidates.
• The company is subject to the risks and uncertainties associated with clinical trials and regulatory approvals.
• The company will need to build out its commercial infrastructure to launch its product candidates in the U.S.

Risks

• The company is subject to the risks and uncertainties associated with clinical trials and regulatory approvals.
• The company may not be able to obtain FDA approval for its product candidates.
• The company may not be able to successfully commercialize its product candidates.
• The company may face competition from other companies developing treatments for presbyopia.
• The company may need to raise additional capital in the future to fund its operations.

Future Outlook

LENZ plans to submit an NDA to the FDA in mid-2024, subject to successful completion of the Phase 3 CLARITY trials, and intends to launch either LNZ100 or LNZ101 in the U.S. with its own commercial organization.

Management Comments

• With clinical activities completed in each of the three Phase 3 CLARITY trials evaluating LNZ100 and LNZ101, we look forward to reporting topline results from these trials in April 2024 and, subject to successful completion of such trials, submitting an NDA to the FDA by mid-year.
• Backed by a strong balance sheet and supported by a proven management team and top-tier investors, we believe it is an exciting time for LENZ as we prepare to execute in a catalyst-rich year and, if approved by the FDA, potentially deliver the first aceclidine-based therapy intended to treat presbyopia.

Industry Context

The announcement highlights the growing interest in pharmaceutical treatments for presbyopia, a condition that affects a large population. The company is positioning itself to compete with existing treatments and to potentially become a leader in the market.

Comparison to Industry Standards

• The company's Phase 2 trial results showed a 71% response rate for LNZ100 and 56% for LNZ101, which is a strong result compared to other treatments for presbyopia.
• The company's product candidates are designed to improve near vision without impacting distance vision, which is a key limitation of other miotics.
• The company's product candidates have a long duration of effect, lasting up to 10 hours, which is longer than some other treatments for presbyopia.
• The company's product candidates have a favorable tolerability profile, with no serious drug-related adverse events reported in clinical trials.
• The company's product candidates have patent protection until 2039, which provides a competitive advantage.

Management Changes

Legal Proceedings

• In connection with the Merger, one complaint has been filed in the United States District Court for the Northern District of California captioned Glen Chew v. Graphite Bio, Inc. et al. , Case No. 3:24-cv-00613 (filed February 1, 2024) and one complaint has been filed in the United States District Court for the District of Delaware captioned Kevin Turner v. Graphite Bio, Inc. et al. , Case No. 1:24-cv-00241-UNA (filed February 22, 2024) (collectively, the Complaints).
• The Complaints generally allege that the Proxy Statement/Prospectus filed by Graphite with the SEC misrepresents and/or omits certain purportedly material information relating to LENZs financial projections, the analyses performed by the financial advisor to Graphites Board of Directors in connection with the Merger, potential conflicts of interest of the financial advisor to Graphites Board of Directors, potential conflicts of interest of Graphites officers, and Graphites liquidation analysis.
• The Complaints assert violations of Section 14(a) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and Rule 14a-9 promulgated thereunder against all defendants (Graphite, its Board of Directors and certain officers) and violations of Section 20(a) of the Exchange Act against Graphites directors and officers.
• The Complaints seek orders enjoining the proposed Merger, or in the event that the proposed Merger is consummated, an order rescinding the Merger or awarding rescissory damages, as well as costs, including attorneys and experts fees.
• Graphite has also received twelve additional demand letters by purported Graphite stockholders from December 14, 2023 to March 20, 2024 seeking additional disclosures in the Proxy Statement/Prospectus (the Demands).
• The Company and the individual defendants intend to vigorously defend against the Complaints, the Demands, and any subsequently filed similar actions.

Related Party Transactions

• In October 2022, the Company issued 9,899,340 shares of its Series A preferred stock for total cash proceeds of $21.3 million to significant shareholders that have designated members on the Companys board of directors and are considered to be related parties.
• In March 2023, the Company issued 22,146,905 shares of its Series B preferred stock for total cash proceeds of $66.0 million to significant shareholders that have designated members on the Companys board of directors and are considered to be related parties.
• A member of our Board of Directors currently serves as a member of the board of directors of one of the Companys vendors, and has served in that capacity since 2023. The Company entered into a Master Services Agreement with this vendor in September 2023 to provide manufacturing services. Accordingly, the Company considers the vendor to be a related party. For the year ended December 31, 2023, fees incurred for services performed by the vendor were $0.3 million, and were charged to research and development expenses. Amounts due to the vendor within accounts payable as of December 31, 2023 totaled $0.3 million.

Stakeholder Impact

• Shareholders of Graphite Bio received a special cash dividend of $1.03 per share.
• Shareholders of LENZ Therapeutics received shares of the combined company.
• Employees of both companies are now part of the combined company.
• Customers of the company may benefit from the development of new treatments for presbyopia.
• The company's suppliers and creditors may be impacted by the merger.

Next Steps

• Report topline results from the Phase 3 CLARITY trials in April 2024.
• Submit an NDA for the selected product candidate in mid-2024 to seek FDA marketing approval.
• Continue to build out U.S. commercial capabilities.
• Explore partnerships for Europe, Canada, and other markets.

Key Dates

Keywords

presbyopia, eye drops, aceclidine, brimonidine, ophthalmic, clinical trials, FDA, NDA, commercialization, biopharmaceutical